Teva Pharmaceutical Industries (NYSE:TEVA) Updates FY 2026 Earnings Guidance

Teva Pharmaceutical Industries (NYSE:TEVA) updated its FY 2026 earnings guidance on Wednesday morning. The company provided EPS guidance of 1.910-2.110 for the period, compared to the consensus earnings per share estimate of 2.170. The company issued revenue guidance of $16.5 billion-$16.9 billion, compared to the consensus revenue estimate of $16.7 billion.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on TEVA shares. UBS Group raised their target price on shares of Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday, April 30th. Truist Financial increased their price target on Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the company a “buy” rating in a report on Thursday, April 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research report on Friday, July 17th. Wall Street Zen downgraded Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. Finally, JPMorgan Chase & Co. raised their target price on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company an “overweight” rating in a report on Thursday, April 30th. Nine investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Teva Pharmaceutical Industries has a consensus rating of “Moderate Buy” and an average target price of $42.00.

Teva Pharmaceutical Industries Trading Up 2.1%

Teva Pharmaceutical Industries stock opened at $35.45 on Friday. The company has a debt-to-equity ratio of 1.70, a quick ratio of 0.78 and a current ratio of 1.01. The firm’s 50-day moving average is $33.22 and its 200-day moving average is $32.72. Teva Pharmaceutical Industries has a 1 year low of $14.99 and a 1 year high of $37.35. The company has a market cap of $40.76 billion, a P/E ratio of 59.09, a PEG ratio of 3.67 and a beta of 0.86.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings results on Tuesday, June 30th. The company reported $0.02 earnings per share for the quarter. Teva Pharmaceutical Industries had a return on equity of 32.59% and a net margin of 4.08%.The business had revenue of $4.14 billion for the quarter. On average, equities analysts expect that Teva Pharmaceutical Industries will post 1.98 earnings per share for the current year.

Insider Buying and Selling

In related news, CAO Amir Weiss sold 10,679 shares of the stock in a transaction that occurred on Wednesday, May 6th. The shares were sold at an average price of $36.00, for a total transaction of $384,444.00. Following the completion of the sale, the chief accounting officer directly owned 20,016 shares of the company’s stock, valued at $720,576. This represents a 34.79% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Richard Daniell sold 30,000 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Tuesday, May 5th. The stock was sold at an average price of $35.40, for a total transaction of $1,062,000.00. Following the completion of the transaction, the executive vice president owned 55,755 shares in the company, valued at approximately $1,973,727. This trade represents a 34.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 300,493 shares of company stock worth $10,537,510 in the last ninety days. 0.54% of the stock is currently owned by corporate insiders.

Teva Pharmaceutical Industries News Roundup

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: An analyst upgrade and favorable price-target commentary boosted sentiment, with coverage highlighting potential for further appreciation. Teva Stock Price Up Following Analyst Upgrade
• Positive Sentiment: Teva raised its 2026 revenue outlook, increasing the midpoint by $75 million, while lifting targets for key innovative brands AUSTEDO, AJOVY and UZEDY. The guidance increase suggests management is gaining confidence in the company’s shift toward higher-value branded medicines. Teva Raises 2026 Revenue Outlook
• Positive Sentiment: UZEDY sales reached a record $77 million in the second quarter, up 43% year over year. Teva raised its 2026 UZEDY revenue outlook to $270 million–$290 million from $250 million–$280 million, supporting expectations for continued growth in long-acting injectable treatments. UZEDY Record Sales and Outlook Increase
• Positive Sentiment: Teva’s three key innovative brands grew 43% year over year in local-currency terms to more than $1 billion in quarterly revenue, helping offset weaker generics sales and reinforcing its “Pivot to Growth” strategy. Teva Q2 Results and Outlook
• Neutral Sentiment: Unusually heavy options activity points to heightened investor interest: call volume rose 136% on July 29, followed by put volume rising 168% on July 30. The mixed activity signals increased speculation rather than a clearly bullish or bearish outlook.
• Negative Sentiment: Second-quarter earnings fell short of expectations. Although revenue slightly beat forecasts, acquisition costs tied to Emalex and impairment charges contributed to a reported net loss of $576 million, compared with net income of $282 million a year earlier. Teva Q2 Earnings Miss

Hedge Funds Weigh In On Teva Pharmaceutical Industries

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. AQR Capital Management LLC grew its holdings in Teva Pharmaceutical Industries by 24.6% in the 1st quarter. AQR Capital Management LLC now owns 23,955 shares of the company’s stock valued at $368,000 after buying an additional 4,732 shares during the last quarter. Focus Partners Wealth increased its holdings in shares of Teva Pharmaceutical Industries by 4.5% during the 1st quarter. Focus Partners Wealth now owns 40,074 shares of the company’s stock worth $616,000 after purchasing an additional 1,739 shares during the period. Franklin Resources Inc. acquired a new position in shares of Teva Pharmaceutical Industries during the second quarter valued at about $255,000. Flow Traders U.S. LLC acquired a new stake in Teva Pharmaceutical Industries during the second quarter worth about $238,000. Finally, Cerity Partners LLC increased its stake in Teva Pharmaceutical Industries by 2.9% during the second quarter. Cerity Partners LLC now owns 45,837 shares of the company’s stock valued at $768,000 after acquiring an additional 1,291 shares during the period. Institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.